
TandemAI Raises $35M in Series A Financing
TandemAI, a Suzhou, and Shanghai, China- and New York-based technology company focused on transforming drug discovery infrastructure, raised $35M in Series A funding.
TandemAI, a Suzhou, and Shanghai, China- and New York-based technology company focused on transforming drug discovery infrastructure, raised $35M in Series A funding.
SHANGHAI, CHINA — Recently, Ronovo Surgical invited top gynecology and urology surgeons to evaluate the performance of its newly unveiled Carina™ RAS Platform, the first modular robotic-assisted surgery (RAS) platform developed in China for laparoscopic procedures.
Oricell Therapeutics, a Shanghai-based pharmaceutical company committed to advancing tumor cellular immunotherapeutics, raised $45M in Series B1 funding.
Eluminex Biosciences, a Suzhou, China and San Francisco, CA-based biotechnology company focusing on ophthalmic diseases and recombinant human collagen technology, raised $40+ M in Series B funding.
Pudo Robotics, a Shenzhen, China-based commercial service robotics manufacturer, raised Over $15M in Series C3 funding.
LanzaTech NZ, Inc., an innovative leader in carbon capture and transformation and a Qiming Venture Partners portfolio company, listed on Nasdaq on Feb 10 Beijing time, following the completion of its business combination with AMCI Acquisition Corp. II (“AMCI”), a special purpose acquisition company.
Ronovo Surgical, a Shanghai, China-based robotic and digital surgery space company, raised $50M+ in funding.
Iaso Biotherapeutics, a Chinese clinical-stage biopharmaceutical company engaged in discovering, developing, and manufacturing innovative cell therapies and antibody products, completed nearly US $75m ($500 million RMB) in Series C1 funding.
LePure Biotech, a Shanghai, China-based provider of a bioprocessing platform, raised an undisclosed amount in Series C funding.
Astro-Energy Technology, a Beijing, China-based provider of household new energy products and systems, riased an undisclosed amount in Seed funding.
Style3D, a Hangzhou, China-based digital solution provider in the global fashion industry, acquired Assyst, a Munich, Germany-based fashion technology company.
LeadArt Biotechnologies, a Boston, MA and Ningbo, China-based biotechnology company focused on drug discovery by automating chemoproteomics processes, raised US$6M in Pre-A funding.
PVmed, a Guangzhou, China-based artificial intelligence (AI) cancer treatment company, raised US$14M in Series A funding.
Full-Life Technologies, a Brussels, Belgium- and Shanghai, China-based radiotherapeutics company, acquired Focus-X Therapeutics, a NJ-based company developing targeted radiopharmaceuticals to treat cancer based on proprietary peptide engineering technology.